A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Korábbi kezelés

• Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving LCAR-AIO treatment.

Más betegség

• Active infections such as hepatitis and tuberculosis.
• Other autoimmune diseases.
• Serious underlying diseases such as tumor, uncontrolled diabetes and clinically significant cardiovascular disease.

• Subjects voluntarily participate in clinical research.
• Age 18-70 years.
• Adequate organ function at screening.
• Clinical laboratory values meet criteria at screening visit.
• Indications include:
  • MS;
• Have been diagnosed of MS at least 6 months before screening.
• Fulfill relapsed/refractory MS conditions.
  • NMOSD/MOGAD:
• Have been diagnosed of NMOSD/MOGAD at least 6 months before screening.
• AQP-4 IgG (NMOSD), or MOG-IgG (MOGAD) should be positive by CBA (Cell based transfection immunofluorescence assay).
• Fulfill relapsed/refractory NMOSD/MOGAD conditions.
  • MG:
• Have been diagnosed of MG at least 6 months before screening.
• AChR-IgG or MuSK-IgG should be positive.
• Fulfill relapsed/refractory NMOSD/MOGAD conditions.